top of page
Search
All Posts


When Innovation Doesn’t Reach Patients: The true cost of Europe’s access crisis is measured in lives
Despite Europe’s reputation for scientific leadership, the truth is that patients across the continent are waiting longer, and often in...
NíoSync
18 hours ago2 min read


Ireland Needs to Rethink Its Biopharma Strategy: From Global Manufacturer to Global Owner
Ireland's biopharma sector is a world-class success story, but what worked in the past will not lead to future success. We've spent...
NíoSync
Jun 53 min read


Political theatre in the U.S., strategic tailwind in Europe — the reality behind Trump’s drug pricing order
Last week, President Trump announced a “Most Favored Nation” policy that would force pharma companies to give the U.S. the lowest global...
NíoSync
Jun 51 min read
bottom of page